Literature DB >> 20938089

Antibodies in cancer immunotherapy.

Lavakumar Karyampudi1, Keith L Knutson.   

Abstract

Monoclonal antibodies are currently being used as potential therapeutics against cancer. So far, eight monoclonal antibodies have been approved by FDA for human use and all these antibodies are effective in the treatment of patients with variety of cancers. Also, there is a long list of several antibodies which are in late stage clinical trials awaiting potential approval by the FDA for use in the clinic. Monoclonal antibodies exert their effects on tumor cells either directly or indirectly thereby eliminating or reducing the tumor burden in cancer patients. In this review we will focus our discussion on different monoclonal antibodies that are currently being used for immunotherapy of different types of cancers, their mechanism of action, several strategies that are being used to improve the effectiveness of these monoclonal antibodies and their potential use in combination therapy approaches along with different chemotherapeutic agents. The field of antibody therapy has ushered in a new and vast research paradigm that is definitely impacting public health.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20938089     DOI: 10.3233/CBM-2009-0141

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  1 in total

1.  A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).

Authors:  Jennifer D Stone; David H Aggen; Andrea Schietinger; Hans Schreiber; David M Kranz
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.